Norepinephrine may promote the progression of Fusobacterium nucleatum related colorectal cancer via quorum sensing signalling.

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101531386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2150-5608 (Electronic) Linking ISSN: 21505594 NLM ISO Abbreviation: Virulence Subsets: MEDLINE

Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience

Quorum Sensing*/drug effects ; Fusobacterium nucleatum*/pathogenicity ; Fusobacterium nucleatum*/drug effects ; Fusobacterium nucleatum*/physiology ; Colorectal Neoplasms*/microbiology ; Norepinephrine*/pharmacology ; Signal Transduction*; Animals ; Mice ; Humans ; Disease Progression ; Fusobacterium Infections/microbiology ; Virulence ; Homoserine/analogs & derivatives ; Homoserine/metabolism ; Mice, Inbred C57BL ; Male ; Lactones

Fusobacterium nucleatum (F. nucleatum) is closely correlated with tumorigenesis in colorectal cancer (CRC). We aimed to investigate the effects of host norepinephrine on the carcinogenicity of F. nucleatum in CRC and reveal the underlying mechanism. The results revealed that both norepinephrine and bacterial quorum sensing (QS) molecule auto-inducer-2 (AI-2) were positively associated with the progression of F. nucleatum related CRC ( p  < 0.01). In vitro studies, norepinephrine induced upregulation of QS-associated genes and promoted the virulence and proliferation of F. nucleatum . Moreover, chronic stress significantly increased the colon tumour burden of Apc ^Min/+ mice infected with F. nucleatum ( p  < 0.01), which was decreased by a catecholamine inhibitor ( p  < 0.001). Our findings suggest that stress-induced norepinephrine may promote the progression of F. nucleatum related CRC via bacterial QS signalling. These preliminary data provide a novel strategy for the management of pathogenic bacteria by targeting host hormones-bacterial QS inter-kingdom signalling.

Expert Rev Proteomics. 2020 Feb;17(2):175-185. (PMID: 32125181)
Front Microbiol. 2021 Oct 06;12:690942. (PMID: 34690943)
PLoS One. 2015 Oct 07;10(10):e0139978. (PMID: 26444281)
Dig Dis Sci. 2018 May;63(5):1210-1218. (PMID: 29508166)
Microorganisms. 2022 Oct 05;10(10):. (PMID: 36296244)
mBio. 2019 Sep 10;10(5):. (PMID: 31506310)
Oncoimmunology. 2019 Jun 10;8(10):e1626192. (PMID: 31646072)
FEMS Microbiol Lett. 1996 Jun 1;139(2-3):155-9. (PMID: 8674983)
J Bacteriol. 1997 Jun;179(12):4043-5. (PMID: 9190823)
Cell Mol Life Sci. 2019 Jun;76(12):2383-2389. (PMID: 30911771)
Oral Microbiol Immunol. 2002 Oct;17(5):296-303. (PMID: 12354211)
J Endocrinol. 2019 Nov 1;244(1):R1-R15. (PMID: 31751295)
Life Sci. 2000 Nov 10;67(25):3075-85. (PMID: 11125844)
Int Immunopharmacol. 2023 Nov;124(Pt B):110971. (PMID: 37748222)
EMBO Rep. 2019 Apr;20(4):. (PMID: 30833345)
Adv Exp Med Biol. 2014;817:157-75. (PMID: 24997033)
Crit Rev Food Sci Nutr. 2019;59(19):3102-3116. (PMID: 29870270)
Arch Oral Biol. 2013 Jan;58(1):17-27. (PMID: 22633049)
Cell Host Microbe. 2013 Aug 14;14(2):195-206. (PMID: 23954158)
Infect Immun. 2010 Mar;78(3):1185-92. (PMID: 20008529)
J Bacteriol. 1994 Jan;176(2):269-75. (PMID: 8288518)
Gastroenterology. 2017 Mar;152(4):851-866.e24. (PMID: 27876571)
Nat Commun. 2020 Jun 26;11(1):3259. (PMID: 32591509)
Oncotarget. 2017 May 9;8(19):31802-31814. (PMID: 28423670)
Transl Oncol. 2019 Jun;12(6):846-851. (PMID: 30986689)
Anal Chem. 2015 Mar 3;87(5):2608-14. (PMID: 25654248)
Cell Rep. 2015 Mar 24;10(11):1861-71. (PMID: 25801025)
Appl Microbiol Biotechnol. 2018 Sep;102(17):7231-7238. (PMID: 29938319)
Am J Physiol Gastrointest Liver Physiol. 2012 Dec 1;303(11):G1288-95. (PMID: 23064760)
Front Microbiol. 2021 Nov 17;12:758870. (PMID: 34867887)
Infect Immun. 2006 Jul;74(7):4021-9. (PMID: 16790775)
Theranostics. 2020 Jan 1;10(1):323-339. (PMID: 31903123)
Nat Commun. 2019 Sep 11;10(1):4129. (PMID: 31511505)
J Bacteriol. 2009 Feb;191(4):1320-9. (PMID: 19011037)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
J Cell Physiol. 2017 Sep;232(9):2359-2372. (PMID: 27512962)
Nat Protoc. 2008;3(6):1101-8. (PMID: 18546601)
Psychoneuroendocrinology. 2015 Feb;52:130-42. (PMID: 25437118)
Cell Host Microbe. 2016 Aug 10;20(2):215-25. (PMID: 27512904)
Cell Metab. 2018 Jun 05;27(6):1348-1355.e4. (PMID: 29805098)
Sci Transl Med. 2020 Dec 2;12(572):. (PMID: 33268511)
Lett Appl Microbiol. 2018 Apr;66(4):340-346. (PMID: 29356014)
Oncotarget. 2015 Oct 13;6(31):32013-26. (PMID: 26397137)
Drug Des Devel Ther. 2020 Jul 30;14:3079-3086. (PMID: 32801646)
Cell Host Microbe. 2013 Aug 14;14(2):207-15. (PMID: 23954159)
Cell. 2017 Jul 27;170(3):548-563.e16. (PMID: 28753429)
Eur J Cancer Prev. 2015 Sep;24(5):373-85. (PMID: 25569450)
Infect Disord Drug Targets. 2021;21(4):623-628. (PMID: 32691717)
Hum Pathol. 2018 Sep;79:93-101. (PMID: 29792893)
mBio. 2016 Jun 07;7(3):. (PMID: 27273829)
J Mol Microbiol Biotechnol. 2010;18(4):195-205. (PMID: 20559013)
Immunity. 2015 Feb 17;42(2):344-355. (PMID: 25680274)

Keywords: Fusobacterium nucleatum; Stress; autoinducer-2; colorectal cancer; norepinephrine

X4W3ENH1CV (Norepinephrine)
6KA95X0IVO (Homoserine)
0 (N-octanoylhomoserine lactone)
0 (Lactones)

Date Created: 20240509 Date Completed: 20240510 Latest Revision: 20240517

20240517

PMC11085999

10.1080/21505594.2024.2350904

38725098